Tcelltech GmbH is a German clinical-stage, biotechnology company developing immunotherapies to cure cancer. The company was founded as a spin-off from DKFZ Heidelberg in 2022. Tcelltech's lead asset “UNIPACT” is a personalized T-cell therapy with large therapeutic potential against multiple cancers. Tcelltech’s UNIPACT leverages two technology platforms: (I) The ultra-fast T-cell receptor identification platform “IMPACT” (II) The novel non-viral gene delivery vector system “nanoSMAR” Besides cell therapies, Tcelltech is also developing two cancer vaccines against brain cancer. The first one targeting IDH-1 has completed a Phase I clinical. The second targeting H3 has recently started a Phase I trial. Tcelltech is actively looking for partnerships to accelerate clinical development and ensure rapid commercialization of its vaccine candidates. Managing Directors: Prof. Dr. Michael Platten, Dr. Edward Green, Dr. Richard Harbottle, Dr. Mathias Turwitt HRB 745600 AG Mannheim